Short Interest in Endo International PLC (ENDP) Decreases By 10.3%
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 19,645,509 shares, a drop of 10.3% from the October 13th total of 21,891,550 shares. Based on an average daily volume of 8,292,797 shares, the short-interest ratio is presently 2.4 days. Currently, 9.8% of the company’s stock are short sold.
Endo International PLC (NASDAQ ENDP) opened at $6.93 on Friday. Endo International PLC has a 1 year low of $5.77 and a 1 year high of $18.63. The company has a debt-to-equity ratio of 10.20, a quick ratio of 0.80 and a current ratio of 1.02. The firm has a market cap of $1,547.57, a PE ratio of 1.43 and a beta of 0.53.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 56.97%. The firm had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. During the same quarter in the prior year, the firm earned $1.01 EPS. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. analysts forecast that Endo International PLC will post 3.54 earnings per share for the current year.
In other Endo International PLC news, CFO Blaise Coleman bought 6,500 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were acquired at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the purchase, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have acquired 16,000 shares of company stock worth $125,460. Company insiders own 0.50% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. James Investment Research Inc. purchased a new stake in shares of Endo International PLC in the 2nd quarter valued at approximately $113,000. Blair William & Co. IL purchased a new position in shares of Endo International PLC during the 2nd quarter worth approximately $126,000. Point View Wealth Management Inc. boosted its position in shares of Endo International PLC by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after purchasing an additional 1,900 shares during the period. Riverhead Capital Management LLC boosted its position in shares of Endo International PLC by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares during the period. Finally, Bank of Hawaii purchased a new position in shares of Endo International PLC during the 2nd quarter worth approximately $180,000. 90.32% of the stock is owned by institutional investors and hedge funds.
ENDP has been the topic of a number of recent analyst reports. Goldman Sachs Group, Inc. (The) initiated coverage on Endo International PLC in a report on Thursday, September 28th. They set a “sell” rating and a $7.00 price target on the stock. Royal Bank of Canada decreased their price target on Endo International PLC from $9.00 to $8.00 and set a “sector perform” rating on the stock in a report on Friday. Cantor Fitzgerald decreased their price target on Endo International PLC from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday. Piper Jaffray Companies reissued a “hold” rating and set a $9.00 price target on shares of Endo International PLC in a report on Sunday, September 17th. Finally, Mizuho reissued a “buy” rating and set a $14.00 price target (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $11.67.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.